(Q35110886)

6 August 2017

1 reference

title

Other immunosuppressive agents for focal segmental glomerulosclerosis (English)

1 reference

focal segmental glomerulosclerosis

6 August 2017

main subject

1 reference

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

25 December 2023

author name string

Claudio Ponticelli

1

1 reference

6 August 2017

Patrizia Passerini

2

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12704585

25 December 2023

publication date

1 March 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0270929503700278?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

https://api.elsevier.com/content/article/PII:S0270929503700278?httpAccept=text/plain

25 December 2023

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

25 December 2023

published in

Seminars in Nephrology

1 reference

6 August 2017

volume

23

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

242-248

1 reference

Management of focal segmental glomerulosclerosis: evidence-based recommendations.

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Focal glomerulosclerosis: natural history and treatment. A report of 70 cases.

25 December 2023

2

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis

25 December 2023

4

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Primary focal segmental glomerulosclerosis: clinical course and response to therapy

25 December 2023

5

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Steroid-dependent nephrotic syndrome in children: Histopathology and relapses after cyclophosphamide treatment

25 December 2023

7

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.

25 December 2023

8

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study

25 December 2023

9

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Idiopathic adult focal segmental glomerulosclerosis: a clinicopathological study and response to steroid

25 December 2023

11

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment

25 December 2023

12

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?

25 December 2023

13

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Treatment of primary focal segmental glomerulosclerosis

25 December 2023

14

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children.

25 December 2023

16

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis

25 December 2023

17

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents

25 December 2023

19

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome

25 December 2023

20

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up

25 December 2023

22

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Aggressive treatment of severe idiopathic focal segmental glomerulosclerosis

25 December 2023

23

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide

25 December 2023

24

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Chlorambucil treatment in minimal lesion nephrotic syndrome: a reappraisal of its gonadal toxicity

25 December 2023

26

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Mycophenolate mofetil treatment for primary glomerular diseases

25 December 2023

31

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome

25 December 2023

32

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis

25 December 2023

33

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Plasmapheresis-induced remission in otherwise therapy-resistant FSGS.

25 December 2023

35

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis?

25 December 2023

37

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys

25 December 2023

38

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis

25 December 2023

39

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome

25 December 2023

41

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome

25 December 2023

42

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.

25 December 2023

43

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy

25 December 2023

45

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy.

25 December 2023

46

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy

25 December 2023

47

1 reference

https://api.crossref.org/works/10.1053/SNEP.2003.50023

25 December 2023

Identifiers

1 reference

6 August 2017

1 reference